Abstract
Introduction: Urachal cancer (UrC) is a rare but aggressive cancer. Due to its low incidence, structured epidemiological data have only rarely been reported. To date, no valid data on UrC are available for the German population. Methods: Data on incidence and relative 5-year survival of urachal lesions (ICD-10: C67.7) were collected from all population-based cancer registries in Germany, provided by the Robert Koch-Institut (RKI). Data were anonymized and included age, sex, and general histology (ICD-O-3). For comparison, a similar inquiry of the “Surveillance, Epidemiology, and End Results program” (SEER-18) database for the USA was conducted. Results: From 2011 to 2015, a total of 154 and 152 cases of UrC were reported for Germany (RKI) and the USA (SEER-18 area), respectively. Age-standardized incidence was 0.32/1,000,000 age-standardized cases/year in both cohorts, and elderly persons were more often affected. The major histological type was adenocarcinoma (64.9 and 81.6%). Relative 5-year survival was 54.8% (CI: 45.0–64.6) in Germany (RKI) and 64.4% (54.1–72.1) in the USA (SEER-18 cohort). Discusssion/Conclusion: The collected data demonstrate low incidence rates and similar epidemiological and clinicopathological characteristics of UrC for both registries. This is the first report of structured epidemiological data for UrC for the German population.
References
1.
Upadhyay
V
, Kukkady
A
. Urachal remnants: an enigma
. Eur J Pediatr Surg
. 2003 Dec
;13
(6
):372
–6
. 2.
Ashley
RA
, Inman
BA
, Sebo
TJ
, Leibovich
BC
, Blute
ML
, Kwon
ED
, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy
. Cancer
. 2006 Aug 15
;107
(4
):712
–20
. 3.
Reis
H
, Krafft
U
, Niedworok
C
, Módos
O
, Herold
T
, Behrendt
M
, et al. Biomarkers in urachal cancer and adenocarcinomas in the bladder: a comprehensive review supplemented by own data
. Dis Markers
. 2018 Mar 12
;2018
:7308168
. 4.
Lopez-Beltran
A
, Paner
, G
, Tsuzuki
T
. Urachal carcinoma
. In: Moch
H
, Humphrey
PA
, Ulbright
TM
, Reuter
VE
, editors. World Health Organization classification of tumours of the urinary system and male genital organs
. Lyon
: IARC
; 2016
. p. 113
–4
.5.
Siefker-Radtke
A
. Urachal adenocarcinoma: a clinician’s guide for treatment
. Semin Oncol
. 2012 Oct
;39
(5
):619
–24
. 6.
Nyirády
P
, Niedworok
C
, Reis
H
, Szarvas
T
. Clinical sequencing-guided therapy of urachal carcinoma: new perspective for a rare cancer
. Eur Urol
. 2016 Nov
;70
(5
):776
–7
. 7.
Szarvas
T
, Módos
O
, Niedworok
C
, Reis
H
, Szendröi
A
, Szász
MA
, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma: a comprehensive review with meta-analysis of 1,010 cases
. Urol Oncol
. 2016 Sep
;34
(9
):388
–98
. 8.
Sirintrapun
SJ
, Ward
M
, Woo
J
, Cimic
A
. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations
. Hum Pathol
. 2014 Feb
;45
(2
):327
–30
. 9.
Cha
S
, Lee
J
, Shin
JY
, Kim
JY
, Sim
SH
, Keam
B
, et al. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
. BMC Cancer
. 2016 Feb 29
;16
:170
. 10.
Collazo-Lorduy
A
, Castillo-Martin
M
, Wang
L
, Patel
V
, Iyer
G
, Jordan
E
, et al. Urachal carcinoma shares genomic alterations with colorectal Carcinoma and may respond to epidermal growth factor inhibition
. Eur Urol
. 2016 Nov
;70
(5
):771
–5
. 11.
Loh
KP
, Mondo
E
, Hansen
EA
, Sievert
L
, Fung
C
, Sahasrabudhe
DM
, et al. Targeted therapy based on tumor genomic Analyses in metastatic urachal carcinoma
. Clin Genitourin Cancer
. 2016 Aug
;14
(4
):e449
–52
. 12.
Módos
O
, Reis
H
, Niedworok
C
, Rübben
H
, Szendröi
A
, Szász
MA
, et al. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: occurence and prognostic significance
. Oncotarget
. 2016 Jun 28
;7
(26
):39293
–301
. 13.
Singh
H
, Liu
Y
, Xiao
X
, Lin
L
, Kim
J
, Van Hummelen
P
, et al. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations
. Oncotarget
. 2016 May 17
;7
(20
):29211
–5
. 14.
Hang
JF
, Pan
CC
. Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma
. Pathology
. 2017 Apr
;49
(3
):316
–7
. 15.
Kardos
J
, Wobker
SE
, Woods
ME
, Nielsen
ME
, Smith
AB
, Wallen
EM
, et al. Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype
. JCO Precision Oncol
. 2017
;1
(1
):1
–12
. 16.
Thiem
S
, Herold
T
, Krafft
U
, Bremmer
F
, Tolkach
Y
, Szász
AM
, et al. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer
. Pathol Int
. 2017 Dec
;67
(12
):597
–601
. 17.
Reis
H
, van der Vos
KE
, Niedworok
C
, Herold
T
, Módos
O
, Szendrői
A
, et al. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
. Int J Cancer
. 2018 Oct 1
;143
(7
):1764
–73
. 18.
Ghazizadeh
M
, Yamamoto
S
, Kurokawa
K
. Clinical features of urachal carcinoma in Japan: review of 157 patients
. Urol Res
. 1983
;11
(5
):235
–8
.19.
Pinthus
JH
, Haddad
R
, Trachtenberg
J
, Holowaty
E
, Bowler
J
, Herzenberg
AM
, et al. Population based survival data on urachal tumors
. J Urol
. 2006 Jun
;175
(6
):2042
–7
. 20.
Wright
JL
, Porter
MP
, Li
CI
, Lange
PH
, Lin
DW
. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder
. Cancer
. 2006 Aug 15
;107
(4
):721
–8
. 21.
Molina
JR
, Quevedo
JF
, Furth
AF
, Richardson
RL
, Zincke
H
, Burch
PA
. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases
. Cancer
. 2007 Dec 1
;110
(11
):2434
–40
. 22.
Bruins
HM
, Visser
O
, Ploeg
M
, Hulsbergen-van de Kaa
CA
, Kiemeney
LA
, Witjes
JA
. The clinical epidemiology of urachal carcinoma: results of a large, population based study
. J Urol
. 2012 Oct
;188
(4
):1102
–7
. 23.
Dhillon
J
, Liang
Y
, Kamat
AM
, Siefker-Radtke
A
, Dinney
CP
, Czerniak
B
, et al. Urachal carcinoma: a pathologic and clinical study of 46 cases
. Hum Pathol
. 2015 Dec
;46
(12
):1808
–14
. 24.
Collins
DC
, Velázquez-Kennedy
K
, Deady
S
, Brady
AP
, Sweeney
P
, Power
DG
. National incidence, management and survival of urachal carcinoma
. Rare Tumors
. 2016 Sep 5
;8
(3
):6257
. 25.
Mylonas
KS
, O Malley
P
, Ziogas
IA
, El-Kabab
L
, Nasioudis
D
. Malignant urachal neoplasms: a population-based study and systematic review of literature
. Urol Oncol
. 2017 Jan
;35
(1
):33
–e19
. 26.
Szarvas
T
, Reis
H
. Editorial Comment from Dr. Szarvas and Dr. Reis to Clinicopathological features of malignant urachal tumor: a hospital-based cancer registry data in Japan
. Int J Urol
. 2020 Feb
;27
(2
):163
–4
. 27.
SEER*Stat Databases: November 2016 Submission [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Result Program; 2016 [cited 2020 Apr 13]. Available from: https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/
.28.
Ederer
F
, Heise
H
. Instructions to IBM 650 programmers in processing survival computations. Methodological note No 10, End results evaluation section
. Bethesda, MD
: National Cancer Institute
; 1959
.29.
Brenner
H
, Gefeller
O
. An alternative approach to monitoring cancer patient survival
. Cancer
. 1996 Nov 1
;78
(9
):2004
–10
. 30.
IARC
. Cancer incidence in five continents
. Lyon
: IARC
; 1976
.31.
Nagumo
Y
, Kojima
T
, Shiga
M
, Kojo
K
, Tanaka
K
, Kandori
S
, et al. Clinicopathological features of malignant urachal tumor: a hospital-based cancer registry data in Japan
. Int J Urol
. 2020 Feb
;27
(2
):157
–62
. 32.
Siegel
RL
, Fedewa
SA
, Miller
KD
, Goding-Sauer
A
, Pinheiro
PS
, Martinez-Tyson
D
, et al. Cancer statistics for Hispanics/Latinos, 2015
, 2018
. CA Cancer J Clin
. 2018 Jan
;65
(6
):457
–80
. 33.
Sheldon
CA
, Clayman
RV
, Gonzalez
R
, Williams
RD
, Fraley
EE
. Malignant urachal lesions
. J Urol
. 1984 Jan
;131
(1
):1
–8
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
